Healthcare

Whirly lollipop on orange background.

GlycoMimetics Tries Again with Lower Price and More Shares

GlycoMimetics (GLYC) paused their deal late last year when the terms were $14 to $16/share with 4M shares offered. This week they are back with a short marketing duration and a lower price of $8/share and 5.7M shares offered plus the typical 15% over allotment. Insiders including Pfizer (PFE) have agreed to buy $14M of…

Keep Reading
Whirly lollipop on orange background.

Biotech IPO Update for May/June

Biotech IPOs are definitely back. In addition to recent pricings we have 4 more deals in active marketing and there were 9 new filings in the last 30 days. We’ve added the recent crop of companies to the roadshow archive. Their descriptions and links are below. Adding up the market capitalizations of just these deals…

Keep Reading
Whirly lollipop on orange background.

GlobeImmune offers little promise for IPO investors.

GlobeImmune (GBIM) is scheduled to price their IPO this week. Wells Fargo and Piper are leading the underwriting group for this $60M IPO (5M shares with a $12 mid-point.) This would put a valuation of $206M on the 36-person company. On the positive side at least one pharma partner (Celgene) is planning to purchase shares…

Keep Reading
Whirly lollipop on orange background.

Pre-IPO Interview with WhiteGlove CEO

We published an interview today with Robert Fabbio, Founder & CEO of WhiteGlove House Call Health, Inc., a company that has filed an S-1 in preparation for an IPO. Please see important disclaimers at the end of the report. The document (PDF) is available via this link: R2 Pre IPO Interview White Glove Final May…

Keep Reading
Whirly lollipop on orange background.

DynaVox Post-IPO Notes

We’ve had DynaVox on our radar screen for some time as makes use of a RealVR technology (speech) to give people with disabilities a way to speak and interact, which fits in with our HealthTech angle. Today the shares were off over 20% to under $12 after their fiscal Q4 report made investors view the…

Keep Reading
Whirly lollipop on orange background.

More IPO Presentations: SurgiVision and Envestnet

SurgiVision is a company we are following because it crosses two major themes we like, health technology and real VR. However, the company is more development stage than we expected. The ability to do surgery based on vision from MRI does seem inevitable, and their technology appears ready, but the pace of adoption is hard…

Keep Reading